Nuvilex (NASDAQ:PMCB – Get Free Report) and Assertio (NASDAQ:ASRT – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.
Volatility & Risk
Nuvilex has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Assertio has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings and target prices for Nuvilex and Assertio, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nuvilex | 1 | 0 | 0 | 0 | 1.00 |
| Assertio | 1 | 4 | 0 | 0 | 1.80 |
Earnings and Valuation
This table compares Nuvilex and Assertio”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nuvilex | N/A | N/A | $30.66 million | ($1.12) | -0.70 |
| Assertio | $102.16 million | 1.49 | -$30.38 million | ($5.69) | -4.13 |
Nuvilex has higher earnings, but lower revenue than Assertio. Assertio is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Nuvilex and Assertio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nuvilex | N/A | 2.13% | 1.69% |
| Assertio | -34.94% | -38.72% | -13.32% |
Insider and Institutional Ownership
34.2% of Nuvilex shares are held by institutional investors. Comparatively, 49.0% of Assertio shares are held by institutional investors. 11.0% of Nuvilex shares are held by insiders. Comparatively, 5.7% of Assertio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Nuvilex beats Assertio on 7 of the 11 factors compared between the two stocks.
About Nuvilex
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
About Assertio
Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Receive News & Ratings for Nuvilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvilex and related companies with MarketBeat.com's FREE daily email newsletter.
